Biocon to expand research base in India with new R&D facility in Chennai

Biocon, as part of its decision to expand its research base in India, has acquired some assets from Pfizer Healthcare to set up its second R&D plant in the country.

Biocon Biologics, a subsidiary of the Bengaluru-based company, has acquired the assets for an undisclosed amount to set up a 60,000 square feet state-of-the-art R&D facility in Chennai.

Christiane Hamacher, CEO, Biocon Biologics, said, “The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide.”

It is expected the centre will be operational in a few months. At present, Biocon has a 200,000 square feet R&D centre at Bengaluru which has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own.

Image Credit : trends.gulte.com

Research Desk

Next Post

USV to invest Rs 400 crore in state-of-the-art formulation plant at Vadodara

Fri Sep 27 , 2019
USV Pvt Ltd has revealed its decision to make a fresh investment of Rs 400 crore on a new state-of-art formulations plant at Vadodara. The oral anti-diabetic drug maker has made this announcement on the back of recent government measure to reduce corporate tax. It is believed to increase capital […]
USV

Categories

Blog Stats